LitAlert ~~ GeneLit.com

    • Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    • Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu , Lee KY, Lindstrom T, Armasu S, Fitz-Gibbon P, Ghosh K, Stan DL, Pruthi S, Neal L, Sandhu N, Rhodes DJ, Klassen C, Peethambaram PP, Haddad TC, Olson JE, Hoskin TL, Goetz MP, Domchek SM, Boughey JC, Ruddy KJ, Couch FJ.
    • J Clin Oncol. 2020 Mar 3:JCO1902190. doi: 10.1200/JCO.19.02190. [Epub ahead of print]
    • How genomic information is accessed in clinical practice: an electronic survey of UK general practitioners.
    • Evans WRH, Tranter J, Rafi I, Hayward J, Qureshi N.
    • J Community Genet. 2020 Mar 3. doi: 10.1007/s12687-020-00457-5. [Epub ahead of print]
    • Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
    • Chevalier LM, Billaud A, Fronteau S, Dauvé J, Patsouris A, Verriele V, Morel A.
    • Mol Diagn Ther. 2020 Mar 2. doi: 10.1007/s40291-020-00452-z. [Epub ahead of print]
    • Genetic testing for epithelial ovarian cancer.
    • Amin N, Chaabouni N, George A.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Jan 16. pii: S1521-6934(20)30017-1. doi: 10.1016/j.bpobgyn.2020.01.005. [Epub ahead of print]
    • PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
    • Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S.
    • Mol Cancer. 2020 Mar 2;19(1):49. doi: 10.1186/s12943-020-01167-9.
    • The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
    • Curtin NJ.
    • Cancers (Basel). 2020 Feb 29;12(3). pii: E564. doi: 10.3390/cancers12030564.
    • Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
    • Widschwendter M, Dubeau L.
    • Cancers (Basel). 2020 Feb 27;12(3). pii: E547. doi: 10.3390/cancers12030547.